WHO Condemns US-Funded Hepatitis B Vaccine Trial in Guinea-Bissau as “Unethical”

The World Health Organization (WHO) has strongly criticized a US-funded clinical trial in Guinea-Bissau, Africa, deeming it “unethical” due to its withholding of a proven, life-saving hepatitis B vaccine from some newborns. The trial, funded by the Centers for Disease Control and Prevention (CDC) under the leadership of Health Secretary Robert F. Kennedy Jr., proposes to randomize 14,000 newborns to receive their first dose of the hepatitis B vaccine either at birth or at six weeks of age.

Concerns Over Scientific Justification and Ethical Safeguards

The WHO’s concerns center around the study’s scientific rationale, ethical protections, and alignment with established research principles involving human subjects. The organization emphasizes that the hepatitis B birth dose vaccine is a well-established and effective public health intervention with a track record spanning over three decades and implementation in more than 115 countries .

Hepatitis B: A Global Health Threat

Hepatitis B is a viral infection that attacks the liver, leading to both acute and chronic disease. According to the WHO, in 2022, an estimated 254 million people were living with chronic hepatitis B infection, with 1.2 million new infections occurring each year . The virus is primarily transmitted from mother to child during birth and delivery, through unsafe injections, or via contact with infected blood or bodily fluids.

Why the Birth Dose is Crucial

The WHO highlights that administering the hepatitis B vaccine at birth is critical for preventing mother-to-child transmission, which occurs in 70-95% of cases. Delaying vaccination puts newborns at risk of contracting a potentially life-threatening infection and developing chronic hepatitis B, increasing their risk of cirrhosis and liver cancer later in life .

Controversial Funding and Research History

The $1.6 million trial is being led by Danish researchers Christine Stabell Benn and Peter Aaby of the Bandim Health Project. These researchers have faced previous criticism for their work on vaccine safety, which has been cited by Kennedy Jr. In his decisions to cut global vaccine funding . The CDC’s funding decision followed a move by Kennedy-appointed advisors to abandon the long-standing universal recommendation for a hepatitis B vaccine birth dose, a decision widely condemned by health experts.

WHO’s Position on Clinical Trials

The WHO asserts that clinical trials withholding a proven effective intervention are only ethically justifiable when no established treatment exists. In the case of the hepatitis B birth dose vaccine, this condition is not met. Providing a life-saving intervention to some newborns while denying it to others is considered potentially harmful and inconsistent with ethical research standards .

Key Takeaways

• The WHO has labeled a US-funded hepatitis B vaccine trial in Guinea-Bissau as “unethical.”
• The trial proposes delaying the first dose of the vaccine for some newborns, a practice the WHO strongly opposes.
• The WHO emphasizes the effectiveness and safety of the hepatitis B birth dose vaccine in preventing mother-to-child transmission.
• The trial’s funding and research leadership have drawn criticism due to past controversies surrounding vaccine safety.